Depletion and pharmacological suppression of USP2 effectively enhance HSP90 inhibitor-incurred ErbB2 downregulation, as well as significantly deter the in vivo and in vitro growth of ErbB2-positive breast cancer cells. Here, USP2 is linked to breast cancer.